NCT03279250View on ClinicalTrials.gov

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

October 13, 2017

Primary Completion Date

May 11, 2021

Study Completion Date

May 11, 2021

Conditions
Prostate AdenocarcinomaStage IIB Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8
Interventions
DRUG

Abiraterone Acetate

Given PO

DRUG

Apalutamide

Given PO

BIOLOGICAL

Gonadotropin-releasing Hormone Analog

Given IM

DRUG

Prednisone

Given PO

PROCEDURE

Radical Prostatectomy

Undergo radical prostatectomy

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT03279250 - Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | Biotech Hunter | Biotech Hunter